Chantal Tasset

3.5k total citations · 3 hit papers
72 papers, 2.3k citations indexed

About

Chantal Tasset is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Chantal Tasset has authored 72 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Genetics, 30 papers in Hematology and 29 papers in Rheumatology. Recurrent topics in Chantal Tasset's work include Chronic Lymphocytic Leukemia Research (40 papers), Rheumatoid Arthritis Research and Therapies (26 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Chantal Tasset is often cited by papers focused on Chronic Lymphocytic Leukemia Research (40 papers), Rheumatoid Arthritis Research and Therapies (26 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Chantal Tasset collaborates with scholars based in Belgium, United States and France. Chantal Tasset's co-authors include Annegret Van der Aa, Pille Harrison, Neelufar Mozaffarian, Florence Namour, Beatrix Bartók, John S. Sundy, Ying Guo, F. Matzkies, Frédéric Vanhoutte and Maria Greenwald and has published in prestigious journals such as The Lancet, JAMA and Gastroenterology.

In The Last Decade

Chantal Tasset

71 papers receiving 2.3k citations

Hit Papers

Clinical remission in pat... 2016 2026 2019 2022 2016 2019 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
    2016 344 citations Séverine Vermeire, Stefan Schreiber et al. The Lancet profile →
  2. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
    2019 224 citations Mark C. Genovese, Kenneth Kalunian et al. profile →
  3. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chantal Tasset Belgium 19 1.4k 711 681 644 492 72 2.3k
Lisy Wang United States 17 1.3k 1.0× 676 1.0× 459 0.7× 421 0.7× 332 0.7× 40 2.0k
Annegret Van der Aa Belgium 17 697 0.5× 402 0.6× 495 0.7× 482 0.7× 302 0.6× 41 1.6k
Chudy I. Nduaka United States 20 732 0.5× 371 0.5× 275 0.4× 275 0.4× 156 0.3× 60 1.9k
David Joske Australia 20 489 0.4× 906 1.3× 400 0.6× 634 1.0× 809 1.6× 45 2.6k
Elena E. Solomou Greece 18 484 0.4× 576 0.8× 1.1k 1.6× 386 0.6× 132 0.3× 70 2.0k
Fabien B. Vincent Australia 19 788 0.6× 157 0.2× 1.2k 1.7× 198 0.3× 146 0.3× 34 1.8k
Serge Jacquot France 17 393 0.3× 140 0.2× 871 1.3× 169 0.3× 153 0.3× 30 1.6k
Massimiliano Bonifacio Italy 23 279 0.2× 979 1.4× 552 0.8× 802 1.2× 417 0.8× 88 2.2k
Alexander W. Hauswirth Austria 26 376 0.3× 488 0.7× 928 1.4× 257 0.4× 298 0.6× 64 2.0k
Tanya Trippett United States 24 206 0.1× 380 0.5× 197 0.3× 655 1.0× 235 0.5× 79 1.9k

Countries citing papers authored by Chantal Tasset

Since Specialization
Citations

This map shows the geographic impact of Chantal Tasset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chantal Tasset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chantal Tasset more than expected).

Fields of papers citing papers by Chantal Tasset

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chantal Tasset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chantal Tasset. The network helps show where Chantal Tasset may publish in the future.

Co-authorship network of co-authors of Chantal Tasset

This figure shows the co-authorship network connecting the top 25 collaborators of Chantal Tasset. A scholar is included among the top collaborators of Chantal Tasset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chantal Tasset. Chantal Tasset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hibi∥, Toshifumi, Satoshi Motoya, Tadakazu Hisamatsu, et al.. (2022). Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research. 21(1). 110–125. 13 indexed citations
2.
3.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2021). Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases. 80(7). 848–858. 163 indexed citations breakdown →
4.
Baraliakos, Xenofon, Mikkel Østergaard, R. B. M. Landewé, et al.. (2021). OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL. Annals of the Rheumatic Diseases. 80. 83–84. 1 indexed citations
5.
Husni, M. Elaine, Dafna D. Gladman, Philip Helliwell, et al.. (2020). FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. Annals of the Rheumatic Diseases. 79. 766–766. 2 indexed citations
6.
Besuyen, R., Mark C. Genovese, Kurt de Vlam, et al.. (2020). P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs. Journal of Crohn s and Colitis. 14(Supplement_1). S350–S352. 1 indexed citations
7.
Helliwell, Philip, Filip Van den Bosch, Laura C. Coates, et al.. (2020). FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). Annals of the Rheumatic Diseases. 79. 765–766. 3 indexed citations
8.
Orbai, Ana‐Maria, Alexis Ogdie, Laure Gossec, et al.. (2019). Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Lara D. Veeken. 59(7). 1495–1504. 22 indexed citations
9.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2019). Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results. Queensland's institutional digital repository (The University of Queensland). 71. 16 indexed citations
10.
Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2019). LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. Annals of the Rheumatic Diseases. 78. 77–78. 25 indexed citations
11.
Genovese, Mark C., René Westhovens, Luc Meuleners, et al.. (2018). Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Research & Therapy. 20(1). 57–57. 44 indexed citations
12.
Namour, Florence, et al.. (2018). Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. British Journal of Clinical Pharmacology. 84(12). 2779–2789. 21 indexed citations
13.
Namour, Florence, et al.. (2016). Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. Drug Metabolism Letters. 10(1). 38–48. 52 indexed citations
14.
Kavanaugh, Arthur, Regina Cseuz, O. V. Reshetko, et al.. (2016). THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study. Annals of the Rheumatic Diseases. 75. 247–247. 11 indexed citations
15.
Kavanaugh, Arthur, Joel M. Kremer, Regina Cseuz, et al.. (2016). Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the Rheumatic Diseases. 76(6). 1009–1019. 176 indexed citations
16.
Vermeire, Séverine, Stefan Schreiber, Robert Petryka, et al.. (2016). Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. The Lancet. 389(10066). 266–275. 344 indexed citations breakdown →
17.
Namour, Florence, et al.. (2014). THU0123 Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach. Annals of the Rheumatic Diseases. 73. 220–221. 1 indexed citations
18.
Richard, M., Duksha Ramful, P.-Y. Robillard, et al.. (2013). Prévalence, gravité et facteurs prédictifs de la dysplasie bronchopulmonaire dans une cohorte ultramarine de grands prématurés. Archives de Pédiatrie. 20(9). 928–937. 3 indexed citations
19.
Reich, Kristian, J.‐P. Ortonne, Alice B. Gottlieb, et al.. (2012). Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. British Journal of Dermatology. 167(1). 180–190. 127 indexed citations
20.
Tasset, Chantal, Véronique Préat, Alfred Bernard, & Marie Cecilie Paasche Roland. (1992). Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats. Antimicrobial Agents and Chemotherapy. 36(7). 1525–1531. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisy Wang Breakdown of academic impact, for papers by Annegret Van der Aa Breakdown of academic impact, for papers by Chudy I. Nduaka Breakdown of academic impact, for papers by David Joske Breakdown of academic impact, for papers by Elena E. Solomou Breakdown of academic impact, for papers by Fabien B. Vincent Breakdown of academic impact, for papers by Serge Jacquot Breakdown of academic impact, for papers by Massimiliano Bonifacio Breakdown of academic impact, for papers by Alexander W. Hauswirth Breakdown of academic impact, for papers by Tanya Trippett
Rankless by CCL
2026